Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Are the New Molecular Assays for CDAD Worth the Cost?

July 20, 2009

Analysis of:Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today | www.medscape.com

The new molecular tests detect of genes of Clustridium difficile. They use primers to amplify the toxin(s) gene and the bacterium. The data that justify their sensitivity versus the current antigen detection assays are based on identification of the bacterium and potential for toxin expression. Since normal people can carry C. difficile, some are gene carriers of the toxins, the molecular tests may lead to more false positive results. The newer molecular assays may not be worth the cost.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS